Fairvalue-Calculator Fairvalue-Calculator
EN DE

Viva Biotech Holdings (VBIZF) Fair Value & Analysis

Healthcare · US · Market cap $281M

Price$0.1349
Fair Value$0.2600
Upside+92.7%
Quality95/100
Evidence: High Range $0.1900 – $0.3200

Fair value as of: Jun 26, 2026

Analysis

Viva Biotech Holdings (VBIZF) currently trades at $0.1349, while our model-based Fair Value estimate is $0.2600 — implying the stock looks roughly 92.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such as medicinal and synthetic chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. It also offers PROTAC/molecular glue services, including protein preparation and complex structure determination, ADME & PK/PD studies of PROTAC molecules, and XDC platforms, such a…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Viva Biotech Holdings (VBIZF) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.2600 versus a price of $0.1349 — about +93% (undervalued). Model-based estimate, not financial advice.
What is the fair value of VBIZF?
Our 21-model fair value for Viva Biotech Holdings is $0.2600 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.1349.
What is the quality score of VBIZF?
Viva Biotech Holdings has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.